Literature DB >> 7533156

IV3 alpha (NeuGc alpha 2-8NeuGc)-Gg4Cer is restricted to CD4+ T cells producing interleukin-2 and a small population of mature thymocytes in mice.

K Nakamura1, H Suzuki, Y Hirabayashi, A Suzuki.   

Abstract

Monoclonal antibody YK-3 was established by immunization with IV3 alpha (NeuGc alpha 2-8NeuGc)-Gg4Cer (GD1c-(NeuGc-NeuGc-)), and its epitope was determined to be NeuGc alpha 2-8NeuGc alpha 2-3Gal beta 1. Thin layer chromatography immunostaining with YK-3 detected only GD1c-(NeuGc-NeuGc-) among the gangliosides of mouse thymocytes and splenocytes. Immunohistochemical staining with YK-3 visualized the medulla of mouse thymus and T cell-dependent areas of mouse spleen and mesenteric lymph nodes. Two-color flow cytometry demonstrated that GD1c (NeuGc-NeuGc-) was expressed on a quarter of CD3+ mature thymocytes and strongly expressed on three quarters of CD4+ T cells in the spleen, lymph nodes, and peripheral blood but not on CD8+ T cells or B cells. GD1c (NeuGc-NeuGc-)-positive cells and negative cells were separated by panning with YK-3 on Petri dishes into adherent and nonadherent fractions. Following stimulation with concanavalin A, adherent cells, predominantly GD1c (NeuGc-NeuGc-)+, produced more interleukin-2 (IL-2) and markedly less interleukin-4 (IL-4) than nonadherent cells. This conclusion is supported by data obtained by lysis of cells by YK-3 and complement. These data indicate that the cell surface expression of GD1c (NeuGc-NeuGc-) is restricted to a small number of mature thymocytes and a subset of CD4+ T cells, which produce abundant IL-2 and very little IL-4, suggesting that GD1c(NeuGc-NeuGc-) is an excellent marker for mouse naive T or T helper 1-like cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533156

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  CD4 and CD8 T cells require different membrane gangliosides for activation.

Authors:  Masakazu Nagafuku; Kaori Okuyama; Yuri Onimaru; Akemi Suzuki; Yuta Odagiri; Tadashi Yamashita; Katsunori Iwasaki; Michihiro Fujiwara; Motoaki Takayanagi; Isao Ohno; Jin-ichi Inokuchi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Targeting ganglioside epitope 3G11 on the surface of CD4+ T cells suppresses EAE by altering the Treg/Th17 cell balance.

Authors:  Zhao Zhao; Bogoljub Ciric; Shuo Yu; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Int Immunol       Date:  2010-08-02       Impact factor: 4.823

Review 3.  Heterogeneity of gangliosides among T cell subsets.

Authors:  Jin-ichi Inokuchi; Masakazu Nagafuku; Isao Ohno; Akemi Suzuki
Journal:  Cell Mol Life Sci       Date:  2012-12-12       Impact factor: 9.261

4.  Neutral glycosphingolipids and gangliosides from spleen T lymphoblasts of genetically different inbred mouse strains.

Authors:  J Müthing
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

5.  9-O-Acetylation of sialomucins: a novel marker of murine CD4 T cells that is regulated during maturation and activation.

Authors:  M Krishna; A Varki
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

6.  Establishment of cells exhibiting mutated glycolipid synthesis from mouse thymus by immortalization with SV-40 virus.

Authors:  Masao Iwamori; Yuriko Iwamori
Journal:  Glycoconj J       Date:  2005-11       Impact factor: 3.009

Review 7.  Involvement of a non-human sialic Acid in human cancer.

Authors:  Annie N Samraj; Heinz Läubli; Nissi Varki; Ajit Varki
Journal:  Front Oncol       Date:  2014-02-19       Impact factor: 6.244

8.  Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.

Authors:  Richard Jennemann; Giuseppina Federico; Daniel Mathow; Mariona Rabionet; Francesca Rampoldi; Zoran V Popovic; Martina Volz; Thomas Hielscher; Roger Sandhoff; Hermann-Josef Gröne
Journal:  Oncotarget       Date:  2017-11-24

Review 9.  The Role of Glycosphingolipids in Immune Cell Functions.

Authors:  Tao Zhang; Antonius A de Waard; Manfred Wuhrer; Robbert M Spaapen
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.